Common Stock, Shares Authorized of KalVista Pharmaceuticals, Inc. from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
KalVista Pharmaceuticals, Inc. quarterly Common Stock, Shares Authorized in shares history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • KalVista Pharmaceuticals, Inc. Common Stock, Shares Authorized for the quarter ending 30 Sep 2025 was 100,000,000, unchanged year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Common Stock, Shares Authorized (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 100,000,000 0 0% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 100,000,000 0 0% 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q1 2025 100,000,000 0 0% 30 Apr 2025 10-Q 11 Sep 2025 2026 Q1
Q4 2024 100,000,000 0 0% 31 Dec 2024 10-Q 10 Nov 2025 2025 Q3
Q3 2024 100,000,000 0 0% 31 Oct 2024 10-Q 05 Dec 2024 2025 Q2
Q2 2024 100,000,000 0 0% 31 Jul 2024 10-Q 05 Sep 2024 2025 Q1
Q1 2024 100,000,000 0 0% 30 Apr 2024 10-K 10 Jul 2025 2025 FY
Q4 2023 100,000,000 0 0% 31 Jan 2024 10-Q 11 Mar 2024 2024 Q3
Q3 2023 100,000,000 0 0% 31 Oct 2023 10-Q 07 Dec 2023 2024 Q2
Q2 2023 100,000,000 0 0% 31 Jul 2023 10-Q 07 Sep 2023 2024 Q1
Q1 2023 100,000,000 0 0% 30 Apr 2023 10-K 11 Jul 2024 2024 FY
Q4 2022 100,000,000 0 0% 31 Jan 2023 10-Q 09 Mar 2023 2023 Q3
Q3 2022 100,000,000 0 0% 31 Oct 2022 10-Q 08 Dec 2022 2023 Q2
Q2 2022 100,000,000 0 0% 31 Jul 2022 10-Q 08 Sep 2022 2023 Q1
Q1 2022 100,000,000 0 0% 30 Apr 2022 10-K 10 Jul 2023 2023 FY
Q4 2021 100,000,000 0 0% 31 Jan 2022 10-Q 10 Mar 2022 2022 Q3
Q3 2021 100,000,000 0 0% 31 Oct 2021 10-Q 09 Dec 2021 2022 Q2
Q2 2021 100,000,000 0 0% 31 Jul 2021 10-Q 09 Sep 2021 2022 Q1
Q1 2021 100,000,000 0 0% 30 Apr 2021 10-K 07 Jul 2022 2022 FY
Q4 2020 100,000,000 0 0% 31 Jan 2021 10-Q 11 Mar 2021 2021 Q3
Q3 2020 100,000,000 0 0% 31 Oct 2020 10-Q 10 Dec 2020 2021 Q2
Q2 2020 100,000,000 0 0% 31 Jul 2020 10-Q 14 Sep 2020 2021 Q1
Q1 2020 100,000,000 0 0% 30 Apr 2020 10-K 13 Jul 2021 2021 FY
Q4 2019 100,000,000 0 0% 31 Jan 2020 10-Q 10 Mar 2020 2020 Q3
Q3 2019 100,000,000 0 0% 31 Oct 2019 10-Q 03 Dec 2019 2020 Q2
Q2 2019 100,000,000 0 0% 31 Jul 2019 10-Q 09 Sep 2019 2020 Q1
Q1 2019 100,000,000 0 0% 30 Apr 2019 10-K 01 Jul 2020 2020 FY
Q4 2018 100,000,000 0 0% 31 Jan 2019 10-Q 14 Mar 2019 2019 Q3
Q3 2018 100,000,000 0 0% 31 Oct 2018 10-Q 14 Dec 2018 2019 Q2
Q2 2018 100,000,000 0 0% 31 Jul 2018 10-Q 14 Sep 2018 2019 Q1
Q1 2018 100,000,000 0 0% 30 Apr 2018 10-K 16 Jul 2019 2019 FY
Q4 2017 100,000,000 0 0% 31 Jan 2018 10-Q 16 Mar 2018 2018 Q3
Q3 2017 100,000,000 0 0% 31 Oct 2017 10-Q 14 Dec 2017 2018 Q2
Q2 2017 100,000,000 0 0% 31 Jul 2017 10-Q 14 Sep 2017 2018 Q1
Q1 2017 100,000,000 0 0% 30 Apr 2017 10-K 30 Jul 2018 2018 FY
Q4 2016 100,000,000 0 0% 31 Jan 2017 10-Q 16 Mar 2017 2016 Q3
Q3 2016 100,000,000 0 0% 30 Sep 2016 10-Q 08 Nov 2016 2016 Q3
Q2 2016 100,000,000 0 0% 30 Jun 2016 10-Q 12 Aug 2016 2016 Q2
Q1 2016 100,000,000 +55,000,000 +122% 31 Mar 2016 10-Q 12 May 2016 2016 Q1
Q4 2015 100,000,000 +55,000,000 +122% 31 Dec 2015 10-Q 08 Nov 2016 2016 Q3
Q3 2015 100,000,000 30 Sep 2015 10-Q 12 Nov 2015 2015 Q3
Q2 2015 100,000,000 30 Jun 2015 10-Q 13 Aug 2015 2015 Q2
Q1 2015 45,000,000 31 Mar 2015 10-Q 21 May 2015 2015 Q1
Q4 2014 45,000,000 31 Dec 2014 10-K 30 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.